U.S. Markets closed

Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks

Stock Research Monitor: QTNT, ADMP, and PETS

LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration. On Wednesday, June 27, 2018, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,445.09, down 1.54%; the Dow Jones Industrial Average edged 0.68% lower, to finish at 24,117.59; and the S&P 500 closed at 2,699.63, down 0.86%. This Thursday morning, WallStEquities.com looks at the performance of these four Healthcare stocks: Quotient Ltd (NASDAQ: QTNT), Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), PetMed Express Inc. (NASDAQ: PETS), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). All you have to do is sign up today for this free limited time offer by clicking the link below.



On Wednesday, shares in Eysins, Switzerland headquartered Quotient Ltd recorded a trading volume of 643,464 shares, which was above their three months average volume of 595.94 thousand shares. The stock ended the session 4.70% lower at $7.90. The Company's shares have gained 68.44% over the previous three months and 14.83% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 30.60% and 58.58%, respectively. Moreover, shares of Quotient, which develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide, have a Relative Strength Index (RSI) of 58.35. Get the full research report on QTNT for free by clicking below at:


Adamis Pharmaceuticals

San Diego, California headquartered Adamis Pharmaceuticals Corp.'s stock closed the day 1.54% lower at $3.20 with a total trading volume of 218,349 shares. The stock is trading below its 50-day moving average by 18.34%. Additionally, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 31.27. Access the free research report on ADMP now by signing up at:


PetMed Express

Shares in Delray Beach, Florida headquartered PetMed Express Inc. recorded a trading volume of 921,552 shares, which was above their three months average volume of 562.88 thousand shares. The stock ended yesterday's trading session 0.30% higher at $46.17. The Company's shares have advanced 23.09% in the past month and 16.27% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 21.62% and 12.94%, respectively. Furthermore, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 77.93.

On June 15th, 2018, research firm CL King initiated a 'Neutral' rating on the Company's stock. Are you already registered with Wall St. Equities? Do so now for free, and get the report on PETS at:


Valeant Pharmaceuticals International

Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock finished Wednesday's session 2.15% lower at $22.81 with a total trading volume of 5.49 million shares. The Company's shares have advanced 47.45% over the previous three months and 37.00% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 5.87% and 26.74%, respectively. Additionally, shares of Valeant Pharma, which operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter products, and medical devices, have an RSI of 46.05.

On June 22nd, 2018, research firm TD Securities downgraded the Company's stock rating from 'Buy' to 'Hold'. Aspiring Member, please take a moment to register below for your free research report on VRX at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities